Immunotherapy in Cancer: turning T cells against cancer
|
|
- Gwendolyn Norton
- 6 years ago
- Views:
Transcription
1 Immunotherapy in Cancer: turning T cells against cancer Frederick L. Locke, MD Director, Immune Cell Therapy Program Department of Blood and Marrow Transplant Cellular Immunotherapy Moffitt Cancer Center
2 Disclosures Consultant: Cellular BioMedicine Group Scientific Advisory Board Member: Kite Pharma Other: Moffitt Cancer Center has received research funding from Kite pharma I will be discussing off-label uses of the following FDA approved medications: Tocilizumab
3
4 Antigen may be processed and presented on MHC molecules, to be recognized by the T cell receptor (TCR) Neefjes et al Nature Reviews Immunology 11:823
5 Productive T cell response requires a second signal (co-stimulation) Pardoll, 2012, Nature Reviews Cancer.
6 Upon T cell activation, inhibitory receptors on the T cell surface are upregulated, turning off the immune response Pardoll, 2012, Nature Reviews Cancer.
7 Ipilimumab, a CTLA-4 blocking antibody, was FDA approved for Malignant Melanoma in 2011 Hodi et al, 2010, NEJM
8 FDA approved Immune Checkpoint Inhibitors Target Drug Indication CTLA-4 PD-1 PD-L1 Ipilimumab (Yervoy) Nivolumab (Opdivo) Pembrolizumab (Keytruda) Atezolizumab (Tecentriq) Melanoma, metastatic Melanoma, adjuvant stage III Melanoma, metastatic Melanoma, adjuvant stage III Renal Cell Carcinoma, advanced Urothelial Carcinoma, metastatic Head and Neck Squamous, recurrent or metastatic Hodgkin Lymphoma, refractory Melanoma, metastatic Non-small cell Lung, with PD-L1 expression Head and Neck Squamous, recurrent or metastatic Hodgkin Lymphoma, refractory Urothelial Carcinoma, metastatic Non-small cell Lung, metastatic
9 In Girl s Last Hope, Altered Immune Cells Beat Leukemia Dec. 9, 2012 New York Times
10 Chimeric Antigen Receptor (CAR) T cell therapy Autologous Cellular Immunotherapy T cells removed and engineered to express a chimeric antigen receptor (CAR) Reprogramed T cells recognize cancer cell targets CD19 targeted CARs are furthest in development
11 Barrett, Curr Opin Pediatr, 2014
12 Pivotal trials of CD19 CAR T cells Company Indication Population Expected FDA approval Kite r/r DLBCL Adults 3Q17 Kite r/r ALL Adults 2Q18 Kite r/r MCL Adults 2Q18 Novartis r/r ALL Pediatrics/AYA 3Q17 CD19 CARs will land FDA approval in
13 Significant Unmet Need in Refractory Aggressive NHL Axicabtagene ciloleucel is an autologous chimeric antigen receptor (CAR) T therapy with a CD3ζ/CD28-based signaling that recognizes and eliminates CD19-expressing cells (anti-cd19) NHL is the most common hematologic malignancy in the US 1 Outcomes in Refractory Aggressive NHL Are Poor - SCHOLAR-1 patient level meta-analysis of refractory NHL 2 ORR of 26% (CR of 8%, PR of 18%) Median OS of 6.6 months NHL, non-hodgkin lymphoma. 1. Howlader N, et al. SEER Cancer Statistics Review, Crump M, et al. J Clin Oncol. 2016;34:7516. Locke & Neelapu et al AACR 2017 #9986
14 ZUMA-1: Multicenter Trial of Axi-cel in Refractory Aggressive NHL Phase 1 Refractory DLBCL/PMBCL/TFL (cohort of n = 6) Phase 2 Cohort 1 Refractory DLBCL (n = 72) Cohort 2 Refractory PMBCL/TFL (n = 20) Primary end point Phase 2: Objective Response Rate (ORR) tested in the first 92 patients dosed a Key secondary end points DOR, OS, safety, levels of CAR T and cytokines a Type 1 error was controlled at the 1-sided level and split between the testing of cohort 1 and cohorts 1 and 2 combined with the exact binomial test comparing observed ORR to a hypothesized rate of 20%. ORR was also assessed in all patients dosed (mitt) and in all patients enrolled (ITT) ASCT, autologous stem cell transplant; axi-cel, axicabtagene ciloleucel; CAR, chimeric antigen receptor; DLBCL, diffuse large B cell lymphoma; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance score; mab, monoclonal antibody; NHL, non-hodgkin lymphoma; OS, overall survival; PMBCL; primary mediastinal B-cell lymphoma; TFL, transformed follicular lymphoma. Locke & Neelapu et al AACR 2017 #9986
15 ZUMA-1: Patient Consort Diagram Patients not treated: SAE (n = 5) No measurable disease (n = 2) Product unavailable (n = 1) SAE (n = 2) Enrolled (n = 111) Conditioning Cy 500 mg/m 2 + Flu 30 mg/m 2 3 d Axi-cel CAR+ cells/kg (N = 101) 22 sites enrolled; 99% manufacturing success rate 91% of enrolled patients received axi-cel 17-day average turnaround time from apheresis to delivery to clinical site Axi-cel, axicabtagene ciloleucel; Cy, cyclophosphamide; Flu, fludarabine; SAE, serious adverse event. Locke & Neelapu et al AACR 2017 #9986 No bridging therapy allowed N = 92: primary analysis (ORR) N = 101: modified intent-totreat (mitt) Data cutoff: January 27, 2017 Median follow-up: 8.7 months
16 ZUMA-1: Met Primary Endpoint ORR (P <.0001) a in Combined Group Best Response Median follow-up of 8.7 months ZUMA-1 Phase 2 DLBCL TFL/PMBCL Combined ORR (%) CR (%) ORR (%) CR (%) ORR (%) CR (%) mitt b n = 77 n = 24 n = a Inferential testing when 92 axi-cel dosed patients had 6 mo of follow-up. ORR 82%, P< b mitt (modified intention-to-treat) set of all patients dosed with axi-cel. CR, complete response; DLBCL, diffuse large B cell lymphoma; ORR; objective response rate; PMBCL; primary mediastinal B-cell lymphoma; TFL, transformed follicular lymphoma. Locke & Neelapu et al AACR 2017 #9986
17 6-month OS Rate 80% in ZUMA-1 vs. 55% in SCHOLAR-1 Median OS (95% CI), mo ZUMA-1 NR (10.5-NR) SCHOLAR ( ) 1. Crump et al. ASCO NR, not reached; OS, overall survival. Locke & Neelapu et al AACR 2017 #9986
18 Duration of Responses At a Median Follow-Up of 8.7 Months ORR 8.2 (3.3-NR) CR NR (8.2-NR) PR 1.9 ( ) CR, complete response; NR, not reached; ORR, objective response rate. Locke & Neelapu et al AACR 2017 #9986
19 6-Month PFS Rates Were Consistent Across Key Covariates Median PFS: 5.9 months (95% CI, ) ASCT, autologous stem cell transplant; IPI, International Prognostic Index; LCI, lower 95% confidence interval; PFS, progression-free survival; UCI, upper 95% confidence interval. Locke & Neelapu et al AACR 2017 #9986
20 Ongoing Complete Remission From ZUMA-1 62-Year-Old Man With Refractory DLBCL Prior therapies R-CHOP R-GDP R-ICE R-lenalidomide Baseline Month 3 Month 12 DLBCL, diffuse large B cell lymphoma; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-GDP, rituximab, gemcitabine, dexamethasone, and cisplatin; R-ICE, rituximab, ifosfamide, carboplatin, and etoposide; R-lenalidomide, rituximab plus lenalidomide. Locke & Neelapu et al AACR 2017 #9986
21 Anti-CD19 CAR T Cell Therapy: Promising Clinical Benefit With a Distinct Adverse Event Profile CRS and NEs are 2 potentially serious adverse events associated with CAR T cell therapy and have also been reported with bispecific antibody therapies Cytokine Release Syndrome Mediated by high levels of inflammatory cytokines, such as IL-6 1 Symptoms include fever, tachycardia, hypotension, and hypoxia 2 Symptoms Neurologic Events Events are associated with high CAR T cell levels and/or high cytokine levels 3,4 Symptoms include confusion, tremor, aphasia, encephalopathy, and seizures 1 CRS and NE are often managed with tocilizumab, an anti IL-6 receptor antagonist and/or corticosteroids for immunosuppression 2 CAR, chimeric antigen receptor; CRS, cytokine release syndrome; IL, interleukin; NE, neurologic events. 1. Lee, et al. Blood. 2014;124: Neelapu, et al. Blood. 2016;128(suppl; abstr):lba Kochenderfer JN, et al. J Clin Oncol Mar 14. [epub ahead of print]. 4. Turtle CJ, et al. J Clin Invest. 2016;126: Locke, et al. AACR 2017 #CT020
22 Summary of AEs AE, n (%) Interim Analysis (N = 62) Primary Analysis (N = 101) Grade 3 AE 59 (95) 95 (95) Grade 3 CRS 11 (18) 13 (13) Grade 3 NE 21 (34) 28 (28) Grade 5 AE 3 (3) a 3 (3) a CRS and NE were generally reversible - All CRS events resolved except 1 case of HLH and 1 case of cardiac arrest - All NE resolved except 1 grade 1 memory impairment 43% received tocilizumab, 27% received steroids No cases of cerebral edema No new axi-cel related grade 5 AEs a As previously reported, grade 5 AEs occurred in 3 patients. Axi-cel related, 2 (2%; HLH and cardiac arrest); axi-cel unrelated, 1 (1%; pulmonary embolism). AE, adverse event; axi-cel, axicabtagene ciloleucel; CRS, cytokine release syndrome; HLH, hemophagocytic lymphohistiocytosis; NE, neurologic event. Locke & Neelapu et al AACR 2017 #9986
23 CAR T Cell Levels Peaked Within 7-14 Days in Patients Treated With Axi-cel axi-cel, axicabtagene ciloleucel; CAR, chimeric antigen receptor; LOD, limit of detection. Locke, et al. AACR 2017 #CT020
24 Expansion of CAR T Cells Was Associated With Objective Response and Grade 3 NE ORR NE CRS CAR AUC defined as cumulative levels of CAR+ cells/µl of blood over the first 28 days post axi-cel. P Values are calculated by Wilcoxon rank sum test. AUC, area under the curve; axi-cel, axicabtagene ciloleucel; CAR, chimeric antigen receptor; CRS, cytokine release syndrome; NE, neurologic events; ORR, objective response rate. Locke, et al. AACR 2017 #CT020
25 CAR T cell and T cell receptor (TCR) therapies are both engineered autologous T cell therapies against tumor targets CAR T-cell TCR Therapy Targets cell surface molecules Does not require HLA match Kershaw et al, Clin Transl Immun, Can target any tumor specific antigen Requires HLA match
26 Tumor infiltrating T cells from a cervical cancer patient were found to be reactive against HPV-16 proteins Draper & Hinrichs, Clin Cancer Res. 2015
27 Anti HPV-16 TCR transduced T cells activate, secrete IFNgamma, and are cytotoxic against HPV Draper and Hinrichs, Clin Can Res, 2015.
28 Ongoing clinical trials are testing out TCR engineered autologous T cell therapy for solid tumors HPV-16 E6 HPV-16 E7 MAGE A3 NY-ESO-1 Clinicaltrials.gov
29 We always overestimate the change that will occur in the next two years and underestimate the change that will occur in the next ten. Don't let yourself be lulled into inaction. Bill Gates
30 Immunology Working Group Abate Daga, Daniel Antonia, Scott Chung, Christine H. Djeu, Julie Y. Linda Kelley Mulé, James J. Mullinax, John E. Pilon-Thomas, Shari A. Ruffell, Brian Sahebjam, Solmaz Sarnaik, Amod A. Soliman, Hatem H. Wei, Sheng Wright, Ken Acknowledgments + Immune Cell Therapy Service Almhanna, Khaldoun Anasetti, Claudio Brayer, Jason B. Chavez, Julio C. Creelan, Ben C. Davila, Marco L. Druta, Mihaela Kharfan-Dabaja, Mohamed A. Fernandez, Hugo Lancet, Jeffrey E. Nishihori, Taiga Pinilla Ibarz, Javier Shah, Bijal Sweet, Kendra L. NCI-K23 Award (Locke) NCI-Cancer Clinical Investigator Team Leadership Award (Locke) Kite Pharma Will Go Jeff Wiezorek Adrian Bot John Rossi Dustin Khiem Sattva Neelapu All investigators and study staff that participated on Zuma 1 Matt Scott Donna Evans Austin Lannon
Chimeric Antigen Receptor - CAR T cell therapy. Frederick L. Locke, MD 2/17/2017
Chimeric Antigen Receptor - CAR T cell therapy Frederick L. Locke, MD 2/17/2017 T cells are immune system cells that normally fight infection Each T cell recognizes a specific target T cells multiply and
More informationState of the art: CAR-T cell therapy in lymphoma
State of the art: CAR-T cell therapy in lymphoma 14 th annual California Cancer Consortium conference Tanya Siddiqi, MD City of Hope Medical Center 8/11/18 Financial disclosures Consultant for Juno therapeutics
More informationBackground. Outcomes in refractory large B-cell lymphoma with traditional standard of care are extremely poor 1
2-Year Follow-Up and High-Risk Subset Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma Abstract 2967 Neelapu SS, Ghobadi A, Jacobson
More informationCAR T-Cell Therapy for Lymphoma: Assessing Long-Term Durability. Julie M. Vose, MD, MBA
CAR T-Cell Therapy for Lymphoma: Assessing Long-Term Durability Julie M. Vose, MD, MBA Relevant Disclosures Research Funding: Kite Pharma/Gilead, JUNO/Celgene, Novartis Honorarium/Ad Boards: Novartis,
More informationCAR-T cell therapy pros and cons
CAR-T cell therapy pros and cons Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma Translational Research
More informationExploiting the Immune System: Chimeric Antigen Receptor-T Cell Therapy for Hematologic Malignancies
Exploiting the Immune System: Chimeric Antigen Receptor-T Cell Therapy for Hematologic Malignancies Maurice Alexander, PharmD, BCOP, CPP Clinical Specialist, Blood and Marrow Transplant UNC Bone Marrow
More informationR/R DLBCL Treatment Landscape
An Updated Analysis of JULIET, a Global Pivotal Phase 2 Trial of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Abstract S799 Borchmann P, Tam CS, Jäger U,
More informationCAR-T Therapy: The Past, The Present, and The Future. Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center
CAR-T Therapy: The Past, The Present, and The Future Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center Objectives Review indications for FDA approved CAR-T therapy
More informationB-Cell NHL and Hodgkin s Disease: Biologicals, Checkpoint Inhibitors, CAR-T cells
B-Cell NHL and Hodgkin s Disease: Biologicals, Checkpoint Inhibitors, CAR-T cells Eduardo M. Sotomayor, MD Director, George Washington Cancer Center Professor, Department of Medicine George Washington
More informationTumor Antigens in the Age of Engineered T cell Therapies
Tumor Antigens in the Age of Engineered T cell Therapies September 30 th 2016 ESMO Preceptorship Course Amsterdam Carsten Linnemann, PhD Senior Scientist Kite Pharma EU B.V. Amsterdam Forward Looking Statements/Safe
More informationObjectives. Emily Whitehead 10/11/2018. Chimeric Antigen Recepetor T-Cells (CAR-T) CAR-T Therapy: The Past, The Present, and The Future
Objectives CAR-T Therapy: The Past, The Present, and The Future Nilay Shah, MD Michael Chargualaf, PharmD, BCOP WVU Medicine Mary Babb Randolph Cancer Center Review indications for FDA approved CAR-T therapy
More informationClinical Advances in Lymphoma
Conflicts of Interest Clinical Advances in Lymphoma Alex F. Herrera, MD Assistant t Professor Department of Hematology and HCT City of Hope BMS research funding (institutional), consultancy Genentech research
More informationDisclosures WOJCIECH JURCZAK
Disclosures WOJCIECH JURCZAK ABBVIE (RESEARCH FUNDING), CELGENE (RESEARCH FUNDING); EISAI (RESEARCH FUNDING); GILEAD (RESEARCH FUNDING); JANSEN (RESEARCH FUNDING); MORPHOSYS (RESEARCH FUNDING), MUNDIPHARMA
More informationSummary... 2 IMMUNOTHERAPY IN CANCER... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 IMMUNOTHERAPY IN CANCER... 3 Sequencing analysis reveals baseline tumour T cell receptor and neo antigen load associates
More informationHighlights in Aggressive Non-Hodgkin Lymphoma From the 2017 American Society of Clinical Oncology Annual Meeting
August 2017 Volume 15, Issue 8, Supplement 8 A SPECIAL MEETING REVIEW EDITION Highlights in Aggressive Non-Hodgkin Lymphoma From the 2017 American Society of Clinical Oncology Annual Meeting A Review of
More informationNY-ESO SPEAR T-cells in Synovial Sarcoma
NY-ESO SPEAR T-cells in Synovial Sarcoma ASCO Update June 6, 2017 Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform
More informationCheckpoint Blockade in Hematology and Stem Cell Transplantation
Checkpoint Blockade in Hematology and Stem Cell Transplantation Saad S. Kenderian, MD Assistant Professor of Medicine and Oncology Mayo Clinic College of Medicine October 14, 2016 2015 MFMER slide-1 Disclosures
More informationImmunocellular Therapies for Relapsed/ Refractory Heme Malignancies: A Focus on CAR T-Cell Therapy
Immunocellular Therapies for Relapsed/ Refractory Heme Malignancies: A Focus on CAR T-Cell Therapy This transcript has been edited for style and clarity and includes all slides from the presentation. This
More informationChimeric An+gen Receptor (CAR) Modified T Cell Therapy: Mee#ng the Unmet Need in Follicular Lymphoma
Chimeric An+gen Receptor (CAR) Modified T Cell Therapy: Mee#ng the Unmet Need in Follicular Lymphoma Stephen J. Schuster, M.D. Director, Lymphoma Program & Lymphoma Translational Research, Abramson Cancer
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationCAR-T CELLS: NEW HOPE FOR CANCER PATIENTS
CAR-T CELLS: NEW HOPE FOR CANCER PATIENTS Natasha Kekre, MD, MPH, FRCPC Hematologist, Blood and Marrow Transplant Program, TOH Associate Scientist, Ottawa Hospital Research Institute Assistant Professor
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More information2018 KSMO Immune Oncology Forum. Immune checkpoint inhibitors in hematologic. malignancies: evidences and perspectives 서울아산병원종양내과 홍정용
2018 KSMO Immune Oncology Forum Immune checkpoint inhibitors in hematologic malignancies: evidences and perspectives 서울아산병원종양내과 홍정용 2018-07-18 Contents Introduction Immune checkpoint inhibtors in lymphomas
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationCorporate Presentation
Corporate Presentation June 2017 Forward-Looking Statements This presentation contains forward-looking statements reflecting management s current beliefs and expectations. These forward looking statements
More informationYESCARTA (axicabtagene ciloleucel)
YESCARTA (axicabtagene ciloleucel) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationImmune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
More informationCancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationKite Pharma: Focused on the Cure. Arie Belldegrun, MD, FACS Chairman, President, & Chief Executive Officer
Kite Pharma: Focused on the Cure Arie Belldegrun, MD, FACS Chairman, President, & Chief Executive Officer Forward Looking Statements/Safe Harbor To the extent statements contained in this presentation
More information-- Manufacturing Success Rate of 99 Percent in ZUMA-1 Pivotal Trial with a Median 17 Day Turnaround Time --
Kite s Yescarta (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationRelapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage
More informationRole of the Pathologist in Guiding Immuno-oncological Therapies. Scott Rodig MD, PhD
Role of the Pathologist in Guiding Immuno-oncological Therapies Scott Rodig MD, PhD Department of Pathology, Brigham & Women s Hospital Center for Immuno-Oncology, Dana-Farber Cancer Institute Associate
More informationMMAE disrupts cell division and triggers apoptosis. Pola binds to cell surface antigen CD79b. Pola is internalized; linker cleaves, releasing MMAE
Adding Polatuzumab Vedotin (Pola) to Bendamustine and Rituximab () Treatment Improves Survival in Patients With Relapsed/Refractory DLBCL: Results of a Phase II Clinical Trial Abstract S802 Sehn LH, Kamdar
More informationEmerging Targets in Immunotherapy
Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationMariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro. Immune checkpoint inhibition in DLBCL
Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro Immune checkpoint inhibition in DLBCL Immunotherapy: The Cure is Inside Us Our immune system prevents or limit infections
More informationCAR T CELL IMMUNOTHERAPY FOR ALL. Stephan Grupp, MD, PhD
CAR T CELL IMMUNOTHERAPY FOR ALL Stephan Grupp, MD, PhD Disclosures Research and/or clinical trial support from Novartis, Servier, Vertex and Kite Study steering committees, consulting, or scientific advisory
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More informationYescarta. Yescarta (axicabtagene ciloleucel) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.105 Subject: Yescarta Page: 1 of 5 Last Review Date: September 20, 2018 Yescarta Description Yescarta
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Yescarta) Reference Number: CP.PHAR.XX Effective Date: 10.31.17 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for
More informationIMMUNE CHECKPOINT THERAPY FOR GENITOURINARY CANCERS: KIDNEY CANCER AND TRANSITIONAL CELL CARCINOMA
IMMUNE CHECKPOINT THERAPY FOR GENITOURINARY CANCERS: KIDNEY CANCER AND TRANSITIONAL CELL CARCINOMA Kathleen Mahoney, M.D., Ph.D. Instructor of Medicine, Harvard Medical School Attending, Beth Israel Deaconess
More informationAdoptive Cell Therapy for Solid Tumours. Sophie Papa 13 th October 2017
Adoptive Cell Therapy for Solid Tumours Sophie Papa 13 th October 2017 Show of Hands Put your hand up if you think the answer is yes to the following statement: Cell therapy will be a routine modality
More informationProfessor Mark Bower Chelsea and Westminster Hospital, London
Professor Mark Bower Chelsea and Westminster Hospital, London Cancer immunotherapy & HIV Disclosures: None Lessons for oncology from HIV Awareness and advocacy Activism Rational drug design Prescribing
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationHave we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES!
Have we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES! Christopher Flowers, MD, MSc Associate Professor Director, Lymphoma Program Department of Hematology and Oncology Emory School of Medicine
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationApril 7, Introduction
April 7, 2017 ICD-10 Coordination and Maintenance Committee Department of Health and Human Services Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244-1850 ICDProcedureCodeRequest@cms.hhs.gov
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationSupplemental Information. Phase 1 Results of ZUMA-1: A Multicenter Study. of KTE-C19 Anti-CD19 CAR T Cell Therapy. in Refractory Aggressive Lymphoma
YMTHE, Volume 25 Supplemental Information Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma Frederick L. Locke, Sattva S. Neelapu,
More informationImmunotherapy on the Horizon
Immunotherapy on the Horizon Andrew L. Coveler Assistant Professor of Medicine, Division of Oncology University of Washington Assistant Member Fred Hutchinson Cancer Research Center Image: NASA.gov 1 2
More informationImmunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center
Immunotherapy for Melanoma Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Conflicts of Interest Bristol-Myers Squibb: -Research support -Participated
More informationCAR T and Other Advances in Immunotherapy. Kathleen Dorritie, MD June 12, 2018
CAR T and Other Advances in Immunotherapy Kathleen Dorritie, MD June 12, 2018 1 Fourth Modality of Cancer Treatment Has Arrived Surgery Radiation Chemotherapy Immunotherapy 2 Nature Rev Cancer. 2009;9:361-371.
More informationCAR T-Cell Therapy for Your Patients: What You Need To Know
CAR T-Cell Therapy for Your Patients: What You Need To Know Marco L. Davila, MD, PhD Associate Member, Blood & Marrow Transplantation and Cellular Immunotherapy Medical Director Cell Therapy Facility H.
More informationTreating for Cure or Palliation: Difficult Decisions for Older Adults with Lymphoma
Treating Frail Adults With Common Malignancies: Best Evidence to Personalize Therapy Treating for Cure or Palliation: Difficult Decisions for Older Adults with Lymphoma Raul Cordoba, MD, PhD Lymphoma Unit
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationAGRESSIVE LYMPHOMAS - FUTURE. Dr Stéphane Doucet CHUM
AGRESSIVE LYMPHOMAS - FUTURE Dr Stéphane Doucet CHUM What are clinical trials? Clinical trials are carefully planned research studies where the most-promising discoveries and results from laboratory studies
More informationLinfoma de Hodgkin. Novos medicamentos. Otavio Baiocchi CRM-SP
Linfoma de Hodgkin Novos medicamentos Otavio Baiocchi CRM-SP 96.074 Hodgkin Lymphoma Unique B-cell lymphoma HRS malignant cells Scattered malignant Hodgkin-Reed-Sternberg (RS) cells in a background of
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationApplying Chimeric Antigen Receptor T cells (CAR-T) to hematologic malignancies
Applying Chimeric Antigen Receptor T cells (CAR-T) to hematologic malignancies Anne W. Beaven, MD Associate Professor Duke University Medical Center Duke Debates April 21, 2017 Chimeric Antigen Receptor
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationPriming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics
Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer
More informationTHE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum
More informationCANCER IMMUNOTHERAPY Presented by John A Keech Jr DO MultiCare Regional Cancer Center
CANCER IMMUNOTHERAPY 2018 Presented by John A Keech Jr DO MultiCare Regional Cancer Center Successful anti-cancer immunity is autoimmunity Green, The Scientist, 2014 Immunotherapy strategies Cancer vaccines
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationChallenges in Distinguishing Clinical Signals to Support Development Decisions: Case Studies
Challenges in Distinguishing Clinical Signals to Support Development Decisions: Case Studies David Feltquate MD, PhD Head of Early Clinical Development, Oncology Bristol-Myers Squibb, Princeton, NJ Challenges
More informationAdoptive Cell Therapy: Treating Cancer
Adoptive Cell Therapy: Treating Cancer with Genetically Engineered T Cells Steven A. Feldman, Ph.D. Surgery Branch National Cancer Institute NCT Conference Heidelberg, Germany September 24, 2013 Three
More informationREMS Program Live Training FOR TRAINING PURPOSES ONLY
REMS Program Live Training FOR TRAINING PURPOSES ONLY This educational module contains information on selected YESCARTA -associated adverse reactions, including cytokine release syndrome and neurologic
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationNow Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
A service of the U.S. National Institutes of Health Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting Trial record 1 of 1 for: Keynote 355 Previous Study Return to List
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationDisclosures. Immunotherapyin Head & NeckCancer. Actual landscape of systemic treatment in HNSCC. Head andneckcanceris an immunogeneic tumor
Immunotherapyin Head & NeckCancer Disclosures Astra-Zeneca/medimmune: clinical trial BMS: advisory board, clinical trial Merck: advisory board, clinical trial, research funding Carla van Herpen Medical
More informationAbstract #163 Michael Kalos, PhD
LONG TERM FUNCTIONAL PERSISTENCE, B CELL APLASIA AND ANTI LEUKEMIA EFFICACY IN REFRACTORY B CELL MALIGNANCIES FOLLOWING T CELL IMMUNOTHERAPY USING CAR REDIRECTED REDIRECTED T CELLS TARGETING CD19 Abstract
More informationHaemato-Oncology ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY. Development and clinical experience Monique Minnema, hematologist
Haemato-Oncology ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Development and clinical experience Monique Minnema, hematologist Consultancy for disclosures Amgen, Celgene, Jansen Cilag, BMS, Takeda Immune
More informationFocus on Immunotherapy as a Targeted Therapy. Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct
Focus on Immunotherapy as a Targeted Therapy Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct 18 2018 Disclosures I have nothing to disclose that is relevant to this presentation. Immunology @ Deeley
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationA Giant Leap in the Treatment Options for Advanced Bladder Cancer
A Giant Leap in the Treatment Options for Advanced Bladder Cancer Yohann Loriot, MD, PhD Department of Cancer Medicine & INSERM U981 Gustave Roussy Villejuif, France Clinical Features of Bladder Cancer
More informationCurrent management of multiple myeloma. Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School
Current management of multiple myeloma Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School JorgeJ_Castillo@dfci.harvard.edu Multiple myeloma MM is a plasma cell neoplasm characterized
More informationManagement of high-risk diffuse large B cell lymphoma: case presentation
Management of high-risk diffuse large B cell lymphoma: case presentation Daniel J. Landsburg, MD Assistant Professor of Clinical Medicine Perelman School of Medicine University of Pennsylvania January
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationImmunotherapy for the Treatment of Cancer
Immunotherapy for the Treatment of Cancer Jason Muhitch, PhD Assistant Professor Department of Urology Department of Immunology Roswell Park Comprehensive Cancer Center Oncology for Scientists March 15,
More informationDisclosures for Dr. Peter Borchmann 48 th ASH Annual meeting, Orlando, Florida
Phase II Study of Pixantrone in Combination with Cyclophosphamide, Vincristine, and Prednisone (CPOP) in Patients with Relapsed Aggressive Non-Hodgkin s Lymphoma P Borchmann Universitaet de Koeln, Koeln,
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationImmunotherapy Overview, Rationale, and Role in Clinical Practice
Immunotherapy Overview, Rationale, and Role in Clinical Practice Financial Disclosure Bradi L. Frei, PharmD, BCOP, BCPS has no relevant financial relationships with commercial interests to disclose. OBJECTIVES
More information